Ascidian Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 48

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $40M

  • Investors
  • 3

Ascidian General Information

Description

Operator of a biotechnology company intended to design exon-editing RNA therapeutics to target the underlying causes of disease. The company excises disease-causing genes and replaces them with wild-type to restore normal protein production in a single reaction with a single construct, helping medical professionals redefine the treatment of disease by rewriting the genetic code.

Contact Information

Website
www.ascidian-tx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 80 Guest Street
  • 4th Floor
  • Boston, MA 02135
  • United States
Primary Industry
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 80 Guest Street
  • 4th Floor
  • Boston, MA 02135
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ascidian Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series A) 08-Nov-2023 $40M Completed Clinical Trials - General
3. Accelerator/Incubator Completed Clinical Trials - General
2. Early Stage VC (Series A) 18-Aug-2020 $50M $50M Completed Startup
1. University Spin-Out 01-Jan-2020 Completed Startup
To view Ascidian’s complete valuation and funding history, request access »

Ascidian Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A
To view Ascidian’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Ascidian Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology company intended to design exon-editing RNA therapeutics to target the underlying causes of
Biotechnology
Boston, MA
48 As of 2026

Cambridge, MA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ascidian Competitors (3)

One of Ascidian’s 3 competitors is Casma Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Casma Therapeutics Venture Capital-Backed Cambridge, MA
Intellia Therapeutics Formerly VC-backed Cambridge, MA
Abeona Therapeutics Corporation Cleveland, OH
You’re viewing 3 of 3 competitors. Get the full list »

Ascidian Patents

  • 30

    Total Documents Applications and Grants

  • Total Patents Families

  • 8

    Granted

  • 17

    Pending

  • Expiring in next 12 mo

Ascidian Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026039524-A1 Msh3 modulatory molecules Pending 14-Aug-2024
AU-2024381558-A1 Mecp2 trans-splicing molecules Pending 14-Nov-2023
EP-4808567-A1 Mecp2 trans-splicing molecules Pending 14-Nov-2023
WO-2025106562-A1 Mecp2 trans-splicing molecules Inactive 14-Nov-2023
AU-2024223513-A1 Htt trans-splicing molecules Pending 15-Feb-2023 C12N15/113
To view Ascidian’s complete patent history, request access »

Ascidian Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ascidian Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Apple Tree Partners (ATP) Venture Capital Minority
University of Pennsylvania University
Penn Center for Innovation Accelerator/Incubator
To view Ascidian’s complete investors history, request access »

Ready to get started?

Request a free trial

Ascidian FAQs

  • When was Ascidian founded?

    Ascidian was founded in 2020.

  • Where is Ascidian headquartered?

    Ascidian is headquartered in Boston, MA.

  • What is the size of Ascidian?

    Ascidian has 48 total employees.

  • What industry is Ascidian in?

    Ascidian’s primary industry is Biotechnology.

  • Is Ascidian a private or public company?

    Ascidian is a Private company.

  • What is the current valuation of Ascidian?

    The current valuation of Ascidian is .

  • What is Ascidian’s current revenue?

    The current revenue for Ascidian is .

  • How much funding has Ascidian raised over time?

    Ascidian has raised $90M.

  • Who are Ascidian’s investors?

    Apple Tree Partners (ATP), University of Pennsylvania, and Penn Center for Innovation have invested in Ascidian.

  • Who are Ascidian’s competitors?

    Casma Therapeutics, Intellia Therapeutics, and Abeona Therapeutics are competitors of Ascidian.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process